ASH 2020 | Iberdomide-based regimens in R/R multiple myeloma
Niels van de Donk, MD, PhD, VU University Medical Center, Amsterdam, Netherlands, discusses the results of a Phase I/II CC-220-MM-001study (NCT02773030) of iberdomide (IBER) with different treatment combinations in relapsed/refractory (R/R) multiple myeloma patients. Patients were divided into separate cohorts receiving IBER plus daratumumab plus dexamethasone (IberDd), or IBER plus bortezomib plus dexamethasone (IberVd). The maximum tolerable dose was not reached and the general safety profile of both treatments was found acceptable, with few serious adverse events being reported. In the IberDd arm, the overall response rate was 42%, compared to 60% in the IberVd cohort. Both triplets were generally tolerable and had promising clinical benefit in R/R multiple myeloma, supporting the continued investigation of IBER-based treatment regimens. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
